Loading, please wait...
RESIDENT SEMINAR SCHEDULE
Wednesday, October 21, 2020
St. Louis College of Pharmacy at University of Health Sciences & Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Beverly Francis, Pharm.D.
Antithrombotic Therapy Following Left Atrial Appendage Closure Using the Watchman Device
|
Cody Craven, Pharm.D.
Utility of Inhaled Nitric Oxide in Acute Pulmonary Embolism
|
(Presentation moved, date pending)
|
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Caroline Crossey, Pharm.D.
Preserving our Knowledge of Treatments for HFpEF: A Review of the Literature
|
Rachel Mehringer, Pharm.D.
Ruxolitinib in Glucocorticoid-Refractory Acute Graft vs Host Disease
|
Kayla Stickler, Pharm.D.
Cannabidiol (CBD): A Review of Pharmacology, Common Therapeutic Uses, and Regulatory Status
|
Please join us for the second Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third floor, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, October 16, 2020 will be able to request parking access on campus.
PARKING
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, October 16, 2020 will be able to request parking access on campus.
PARKING
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT
Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close October 28, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Oct 21, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
3.75
Activity Type
- Knowledge
For patients with nonvalvular atrial fibrillation who need an alternative to oral anticoagulants, the WATCHMAN Implant is a minimally invasive procedure approved in March 2015 for LAA occlusion. It is the most studied left atrial appendage closure (LAAC) device with over 10 clinical trials conducted. Therefore, LAA occlusion is an alternative therapy for stroke prevention in this patient population. Antithrombotic therapy post-WATCHMAN device placement is recommended for a short period of time to prevent device-associated thrombus. However, the preferred antithrombotic therapy is not clearly outlined and is highly patient-specific. Many antithrombotic therapies have been studied after WATCHMAN device implantation which include warfarin, DOACs, DAPT, aspirin monotherapy, or no therapy at all. In the PREVAIL and PROTECT AF trials, the post-WATCHMAN device implantation
anticoagulation/antiplatelet regimen is one of the most widely used. This therapy consists of a short course of warfarin follow by DAPT (clopidogrel and aspirin) then transitioning to aspirin monotherapy indefinitely. The EWOLUTION trial used variable regimens and further study on this demonstrated that treatment with DOACs and DAPT was similar to treatment with warfarin in terms of device thrombus, stroke, and bleeding risk. The ASAP trial used DAPT followed by aspirin indefinitely which reported a large risk reduction of stroke compared to the expected stroke risk based on CHADS2 score. These trials and their use of antithrombotic agents in patients with atrial fibrillation post-WATCHMAN device implantation will be discussed in detail to aid healthcare professionals with selection of appropriate regimens for this patient population.
anticoagulation/antiplatelet regimen is one of the most widely used. This therapy consists of a short course of warfarin follow by DAPT (clopidogrel and aspirin) then transitioning to aspirin monotherapy indefinitely. The EWOLUTION trial used variable regimens and further study on this demonstrated that treatment with DOACs and DAPT was similar to treatment with warfarin in terms of device thrombus, stroke, and bleeding risk. The ASAP trial used DAPT followed by aspirin indefinitely which reported a large risk reduction of stroke compared to the expected stroke risk based on CHADS2 score. These trials and their use of antithrombotic agents in patients with atrial fibrillation post-WATCHMAN device implantation will be discussed in detail to aid healthcare professionals with selection of appropriate regimens for this patient population.
Objectives
- Identify the potential benefit(s) of WATCHMAN device implantation vs. warfarin in patients with atrial fibrillation
- Identify appropriate Antithrombotic Therapy Following Left Atrial Appendage Closure Using the Watchman Device
Speaker(s)/Author(s)
|
Beverly Francis, Pharm.D. |
Activity Number
0033-0000-20-052-L01-P
Date:
10/21/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Acute pulmonary embolism (PE) is characterized by direct thrombotic occlusion of the pulmonary vasculature. However, the associated mortality risk is driven by an increase in pulmonary vascular resistance and afterload resulting in decompensated right ventricular failure. Right ventricular dysfunction also contributes to ventilation-perfusion abnormalities that further exacerbate dyspnea and hypoxemia. Inhaled vasodilators have been hypothesized to provide benefit in the setting of PE via their ability to modulate the production of cyclic guanosine monophosphate leading to decreased pulmonary arterial pressure. Nitric oxide, in particular, is an intriguing agent given the relative deficiency of nitric oxide in patients with PE. In this seminar, we will discuss the current perspective on the use of inhaled nitric oxide in patients with PE as well as the clinical challenges that may arise with its use. Finally, the available literature will be critiqued and recommendations for use provided.
Speaker(s)/Author(s)
|
Cody Craven, Pharm.D. |
Activity Number
0033-0000-20-050-L01-P
Date:
10/21/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 406 and Virtually
There has been a longstanding debate on if a patient with out of hospital cardiac arrest should be routinely administered sodium bicarbonate. In the past, ACLS and AHA guidelines supported the use of sodium bicarbonate, however, updated guidelines recommend against it. Some literature suggests that the routine use of sodium bicarbonate increases the percentage of return of spontaneous circulation. Other literature disputes the notion that routine use of sodium bicarbonate is beneficial and suggests that its use is in fact harmful. This seminar will focus on patient survival and neurological function in patients who experienced out of hospital cardiac arrest and were administered sodium bicarbonate versus those who received standard care to assess its place in therapy.
Speaker(s)/Author(s)
|
Samantha Grimm, Pharm.D. |
Activity Number
0033-0000-20-042-L01-P
Date:
10/21/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
Objectives
- Identify the potential bene?t(s) of mineralocorticoid receptor antagonist therapy in patients with HFpEF.
- Select appropriate pharmacologic therapy in patients with HFpEF to reduce hospitalizations.
Speaker(s)/Author(s)
|
Caroline Crossey, Pharm.D. |
Activity Number
0033-0000-20-053-L01-P
Date:
10/21/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Hemp and marijuana are two well-known products from the plant Cannabis sativa, which vary drastically in their utility and composition. Hemp is defined as containing <0.3% THC (tetrahydrocannabinol) and has recently been legalized federally in the United States. The change in legal status has allowed for a multitude of over the counter cannabidiol (CBD) products to be sold. CBD products are not regulated by the Food and Drug Administration (FDA), and limited robust clinical trials have been conducted to determine therapeutic benefits of CBD products. The objective of this lecture is to educate pharmacists on the pharmacology, utility, and legal status of over the counter CBD products to increase preparedness for discussion on CBD products with patients and colleagues.
Speaker(s)/Author(s)
|
Kayla Stickler, Pharm.D. |
Activity Number
0033-0000-20-051-L01-P
Date:
10/21/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
